



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

0420
oyed
5-18-01

Applicant: Ramnarayan *et al.*

Serial No: 09/709,905

Filed: November 10, 2000

For: USE OF COMPUTATIONALLY DERIVED
PROTEIN STRUCTURES OF GENETIC
POLYMORPHISMS IN
PHARMACOGENOMICS FOR DRUG
DESIGN AND CLINICAL APPLICATIONS

Art Unit: Unassigned

Examiner: Unassigned

I hereby certify that this paper and the attached
papers are being deposited with the United States
Postal Service as first class mail in an envelope
addressed to:
Commissioner for Patents
Washington, D.C. 20231, on this date.

03/21/01
Date

Kelly Fischer
Kelly Fischer

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is a Preliminary Amendment for filing in connection
with the above-identified application.

(X)

The Commissioner is hereby authorized to charge the fee for the Information
Disclosure Statement and any other fees that may be due under 37 C.F.R.
§§1.16-1.17 in connection with this paper or with this application during
its entire pendency to Deposit Account No. 50-1213. A duplicate of this
sheet is enclosed.

Respectfully submitted
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman
Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No.: 24737-1906C
Address all correspondence to:
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4250 Executive Square, 7th Floor
La Jolla, California 92037-9103
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com

04/10/2001 SDIRETA1 00000105 501213 09709905

01 FC:126

180.00 CH



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ramnarayan *et al.*
Serial No. 09/709,905
Filed: November 10, 2000
For: USE OF COMPUTATIONALLY DERIVED
PROTEIN STRUCTURES OF GENETIC
POLYMORPHISMS IN
PHARMACOGENOMICS FOR DRUG DESIGN
AND CLINICAL APPLICATIONS
Art Unit: Unassigned
Examiner: Unassigned

I hereby certify that this paper and the attached
papers are being deposited with the United States
Postal Service as first class mail in an envelope
addressed to:
Commissioner for Patents
Washington, D.C. 20231, on this date.

03/21/01
Date

Kelly Fischer
Kelly Fischer

#41B
Plunkett
4/27/02

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Preliminary to the examination of the above-captioned application, please
amend the application as follows:

IN THE DRAWINGS:

Please amend the drawings according to the attached set of figures, on
which the amendment is indicated in red ink. Specifically, in Figure 4, please the
box around the legend for visual clarity; in Figure 6, please remove the extra wedge
in between the amido group and cyplopentyl group in structure of Indinavir; and in
Figure 7, please move the word "Frequency" to the y-axis, as shown on the hand
annotated pages.

REMARKS

Any fees that may be due in connection with filing this paper, or during the
entire pendency of this application, may be charged to Deposit Account No. 50-
1213.

Amendments have been made to Figures 4, 6, and 7 to correct typographical